Apeloa Pharmaceutical Co.,Ltd
XSEC:000739 Stock Report
Apeloa PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 5/6 Apeloa PharmaceuticalLtd has a total shareholder equity of CN¥6.6B and total debt of CN¥939.9M, which brings its debt-to-equity ratio to 14.3%. Its total assets and total liabilities are CN¥13.3B and CN¥6.8B respectively. Apeloa PharmaceuticalLtd's EBIT is CN¥1.1B making its interest coverage ratio -16.5. It has cash and short-term investments of CN¥3.9B.
Key information
14.3%
Debt to equity ratio
Interest coverage ratio -16.5x Cash CN¥3.89b Equity CN¥6.59b Total liabilities CN¥6.75b Total assets CN¥13.34b
Recent financial health updates
Show all updates
Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.21 in 3Q 2023) Oct 18
Investor sentiment improves as stock rises 22% Sep 30
Apeloa Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 18, 2024 Sep 30
Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.31 in 2Q 2023) Aug 16
Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 16, 2024 Jun 29
Dividend increased to CN¥0.32 May 18
First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 1Q 2023) Apr 19
Apeloa Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 19, 2024 Mar 30 Apeloa Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 09, 2024
Apeloa Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 09, 2024 Mar 08
Full year 2023 earnings released: EPS: CN¥0.90 (vs CN¥0.84 in FY 2022) Mar 08
Investor sentiment improves as stock rises 17% Feb 09
Apeloa Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Mar 08, 2024 Dec 29
Investor sentiment deteriorates as stock falls 16% Oct 25
Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 3Q 2022) Oct 19
Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2023 Results on Aug 15, 2023 Jul 01
Apeloa Pharmaceutical Co.,Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 22 May 2023 May 17
Full year 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.81 in FY 2021) Mar 10
Third quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.18 in 3Q 2021) Oct 21
Investor sentiment improved over the past week Oct 15
First half 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.47 in 1H 2021) Jul 29
Investor sentiment improved over the past week May 11
Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) announces an Equity Buyback for CNY 400 million worth of its shares. May 06
First quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.18 in 1Q 2021) Apr 27
Apeloa Pharmaceutical Co.,Ltd Proposes Final Dividend on A Shares for the Year 2021, Payable on 18 April 2022 Apr 13
Apeloa Pharmaceutical Co.,Ltd Announces Cash Dividend for 2021 Apr 03
Investor sentiment improved over the past week Mar 16
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 10
Investor sentiment deteriorated over the past week Oct 28
Third quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 3Q 2020) Oct 23
Investor sentiment improved over the past week Sep 18
Second quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.23 in 2Q 2020) Aug 19
Investor sentiment improved over the past week Jun 30
Investor sentiment deteriorated over the past week May 29
First quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.13 in 1Q 2020) Apr 20
Full year 2020 earnings released: EPS CN¥0.69 (vs CN¥0.47 in FY 2019) Mar 12
Revenue misses expectations Mar 12
New 90-day high: CN¥25.52 Feb 24
Apeloa Pharmaceutical Co.,Ltd to Report Fiscal Year 2020 Results on Mar 12, 2021 Jan 22
New 90-day high: CN¥24.79 Jan 21
Third quarter earnings released Oct 23
New 90-day low: CN¥22.50 Oct 16
Apeloa Pharmaceutical Co.,Ltd to Report Q3, 2020 Results on Oct 22, 2020 Oct 16
New 90-day high - CN¥27.14 Aug 21
Earnings released Aug 18
New 90-day high - CN¥25.93 Aug 05
Apeloa Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 18, 2020 Jul 23
Financial Position Analysis
Short Term Liabilities: 000739's short term assets (CN¥8.8B) exceed its short term liabilities (CN¥6.5B).
Long Term Liabilities: 000739's short term assets (CN¥8.8B) exceed its long term liabilities (CN¥274.9M).
Debt to Equity History and Analysis
Debt Level: 000739 has more cash than its total debt.
Reducing Debt: 000739's debt to equity ratio has increased from 2.7% to 14.3% over the past 5 years.
Debt Coverage: 000739's debt is well covered by operating cash flow (143.5%).
Interest Coverage: 000739 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}